查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447728

慢性荨麻疹市场评估：按治疗、诊断、给药途径、最终用户和地区划分的机会和预测（2017-2031）

Chronic Spontaneous Urticaria Market Assessment, By Treatment, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球慢性荨麻疹市场规模将从2023年的20.1亿美元增长到2031年的49.5亿美元，2024-2031年预测期间复合年增长率为11.93%。预计将增长至。

多种因素正在推动全球已形成慢性荨麻疹市场。 由于突破性的发现和对该疾病的了解的加深，慢性荨麻疹的全球市场正在显着扩大。

彻底阐明荨麻疹的基本机制有助于开发更强大的治疗药物。 随着製药公司和医疗保健提供者增加研发资金，新的治疗方法也不断被发现并推向市场。 随着对慢性荨麻疹病理生理学的了解不断深入，人们开发出更有效、更有针对性的药物，与传统方法相比，这些药物可以更好地缓解症状。 全球慢性荨麻疹市场也受到皮下给药的影响。 这种方法非常有效，因为它可以让药物完全吸收，而不会影响患者的末梢系统，也不存在损伤血管或神经的可能性。

2023 年 8 月，诺华报告了 III 期 REMIX-1 和 REMIX-2 研究的阳性顶线数据，该研究评估了 BTK 抑制剂瑞布替尼 25 mg b.i.d. 对慢性荨麻疹患者的疗效。 如果获得批准，瑞米布替尼可能成为十年来第一个治疗慢性荨麻疹的药物，为60% 对H1 抗组织胺没有反应的患者提供一种简单而有效的替代方案。

大力投资促进研发

全球慢性荨麻疹市场的成长也得益于製药公司对研发活动的持续关注。 市场主要参与者正在投资数十亿美元的研究工作，以寻找治疗慢性荨麻疹患者的创新解决方案。 透过研究，公司可以深入了解这种疾病治疗的相关因素。

大量投资改善医疗基础建设

鑑于对高效慢性荨麻疹治疗的需求不断增长，全球慢性荨麻疹市场的主要参与者正在加紧努力透过投资改善医疗基础设施。 这种经过深思熟虑的行动是由于慢性荨麻疹发生率上升而引发的。 慢性荨麻疹是一种以无明显原因突然发作的肿胀和荨麻疹为特征的疾病。 透过向医疗基础设施投入更多资金，这些公司希望创造和提供新的、更强大的治疗方法。 除了表现出致力于满足慢性荨麻疹患者未满足的需求之外，这项投资还将显着推动市场发展，因为更好的治疗方法会带来更好的患者结果，并增加对尖端治疗方法的需求。这表明这是可能的。

本报告调查了全球慢性荨麻疹市场，提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争格局、主要公司简介等等。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球慢性荨麻疹市场展望

  • 市场规模/预测
  • 透过治疗
    • 药物
    • 血浆置换
    • 光疗
    • 其他
  • 透过诊断
    • 验血
    • 过敏测试
    • 身体检查
    • 其他
  • 依给药途径
    • 口头
    • 本地
    • 注射用
    • 其他
  • 按最终用户
    • 医院
    • 专科诊所
    • 居家护理
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球慢性荨麻疹市场展望：按地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 透过治疗
  • 透过诊断
  • 依给药途径
  • 按最终用户
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AstraZeneca plc

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11135

The chronic spontaneous urticaria market is projected to witness a CAGR of 11.93% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 4.95 billion in 2031. Various factors are shaping the global chronic spontaneous urticaria market such as the increasing prevalence of chronic spontaneous urticaria, significant investments in research and development, availability of suitable medications for treatment, clinical advantages of subcutaneous drugs, and increasing number of clinical trials. The global chronic spontaneous urticaria market, which is defined by recurring hives and angioedema without known triggers, is expanding significantly due to breakthrough discoveries and a better comprehension of the illness.

The creation of more potent treatments is being fueled by a more thorough investigation of the fundamental mechanisms of CSU. New therapeutic options are being discovered and introduced in the market through increased research and development funding from pharmaceutical companies and healthcare providers. Improved knowledge of the pathophysiology of CSU is leading to more effective tailored medicines that provide better symptom alleviation than conventional approaches. The global chronic spontaneous urticaria market is affected by the ability to administer medications subcutaneously. The method is highly effective as it allows complete absorption of the drug without affecting patient's peripheral system and no chances of injury to the vessels and nerves.

Novartis reported positive top-line data in August 2023 from the Phase III REMIX-1 and REMIX-2 studies assessing the BTK inhibitor remibrutinib 25 mg b.i.d. in patients with chronic spontaneous urticaria (CSU). Remibrutinib, if authorized, could be the first medication in a decade to treat chronic spontaneous urticaria (CSU), providing a straightforward and efficient alternative for 60% of patients for whom H1-antihistamines are ineffective.

Significant Investments for Expediting Research and Development

The growth of global chronic spontaneous urticaria market is being driven by a constant focus on research and development activities by pharmaceutical companies. Major companies in the market are spending huge amounts in conducting research activities to find innovative solutions for treating patients with CSU. Through research, companies can discover various insights into the factors revolving around the treatment of the disease. All these factors indicate that there is a strong association between the research efforts and the increasing growth trajectory of the global chronic spontaneous urticaria market. In January 2024, Enanta Pharmaceuticals, a clinical-stage biotechnology company, provided updates on its research and development programs and the outlook for the year 2024, at the 42nd Annual J.P. Morgan healthcare conference. The company announced its expansion into immunology and discovery programs to treat CSU.

Significant Investments for Improving Healthcare Infrastructure

Noticing the increasing need for efficient CSU therapies, major players in the global chronic spontaneous urticaria market are stepping up their efforts to improve healthcare infrastructure through investments. The calculated action is motivated by the rising incidence of CSU, a disorder marked by swelling and hives that develop suddenly and have no apparent reason. These businesses hope to create and offer novel, more potent treatment alternatives by investing more money in the healthcare infrastructure. In addition to demonstrating their dedication to meet the unmet needs of CSU patients, the investment shows the market has the potential to develop significantly due to better treatments resulting in favorable patient outcomes and a rise in demand for cutting-edge therapies.

Many companies in the global chronic spontaneous urticaria market are increasing their investments in the market. For instance, in April 2023, Evommune, Inc. announced the completion of USD 50 million Series B financing to develop new innovative technologies to treat inflammatory diseases such as CSU. Along with current investors EQT Life Sciences and SymBiosis, new investor Arix Bioscience led the funding.

Availability of Novel Medications for Treatment

The development and accessibility of therapeutic alternatives, such as immunosuppressants, biologic therapies, and antihistamines, are the main factors driving the global chronic spontaneous urticaria market. These medications are highly effective due to which their demand in the market is increasing drastically. Medical research advancements have led to the development of many such medications, with more under clinical trials. Second-line drugs like leukotriene receptor antagonists (like montelukast), oral corticosteroids (like prednisone), H2 blockers (like cimetidine), and biologics (like omalizumab; Xolair) may be prescribed to treat patients with refractory symptoms. In January 2024, Evommune, Inc., a clinical-stage biotechnology company, announced the beginning of its human study for Phase 1, to find out EVO756 in adults with CSU. If the trial turns out to be successful, then EVO756 can be the first oral treatment for several diseases such as CSU and inflammatory itch.

Clinical Advantages of Subcutaneous Drugs

Subcutaneous drugs absorb easily without any side effects. Subcutaneous drugs offer numerous clinical benefits such as patient convenience, reduced cost, fewer side effects, enhanced patient satisfaction, and improved drug absorption. With less frequent doses and consistent medication absorption, it can potentially minimize the need for hospital visits and increase patient compliance by enabling self-administration at home. Subcutaneous drugs are highly effective offering a reliable treatment for CSU. Home administration eliminates the need for expensive hospital visits and decreases the demand for medical personnel, resulting in lower healthcare expenses. Compared to intravenous administration, subcutaneous administration often leads to fewer adverse events, particularly those related to infusions, such as infections and hypersensitivity reactions.

On February 16, 2024, Genentech, a member of Roche Group, announced Xolair for the treatment of anaphylaxis and allergic reactions caused due to food allergies in children and adults. It received approval from the U.S. Food and Drug Administration (FDA) and has been cleared for use of treating CSU.

Asia-Pacific to Grow at the Fastest Rate During the Forecast Period

Several countries in Asia-Pacific are going to observe rapid growth in the global chronic spontaneous urticaria market. Economic growth in countries like China and India is going to play a major role in market expansion along with the countries such as China, Japan, India, Australia, and South Korea. The trend can be attributed to the region's increasing population growth, government initiatives, and improving healthcare infrastructure. People are becoming more aware of the illness and its implications, which increases the demand for effective therapies. Additionally, by giving patients more treatment options, the emergence of new pharmaceutical businesses in the market with a focus on cutting-edge CSU therapy promotes market expansion.

On 16 February 2024, Dupixent, a drug used for the treatment of CSU, jointly developed by Sanofi and Regeneron, was granted permission for manufacturing and marketing by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Future Market Scenario (2024 - 2031F)

To handle the complexity of CSU, businesses are actively seeking novel solutions. For example, Amalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), was developed and is now authorized for use in CSU.

It is anticipated that the creation of novel diagnostic instruments and methodologies will enhance the precision and promptness of CSU diagnosis, resulting in improved patient outcomes. For instance, blood and skin prick tests can be used to determine the underlying cause of CSU, which enables doctors to adjust treatment regimens accordingly.

Advancement in treatment options like targeted therapies and biologics will lead to the expansion of the global spontaneous urticaria market.

Patients are more likely to receive access to cutting-edge CSU medicines and treatments as global healthcare spending rises.

Key Players Landscape and Outlook

The chronic spontaneous urticaria market is expected to experience significant growth in the coming years, driven by factors such as increasing prevalence of urticaria, rising healthcare spending, and technological advancements in medicine and digital health. The market is highly competitive, with key players including Roche, Novartis, Sanofi, AstraZeneca, and GlaxoSmithKline, and others. The global chronic spontaneous urticaria market is witnessing a significant shift towards strategic partnerships among leading companies in the industry. By working together, these organizations can overcome technical and clinical barriers that would otherwise prevent them from moving forward independently.

A Complete Response Letter (CRL) for the supplementary Biologics Licence Application for Dupixent was made available by the U.S. FDA in October 2023. A medication called Dupixent used to treat CSU, is being developed in collaboration with the American biotechnology company Regeneron and Sanofi.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Spontaneous Urticaria Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Treatment
    • 4.2.1.Medication
    • 4.2.2.Plasmapheresis
    • 4.2.3.Phototherapy
    • 4.2.4.Others
  • 4.3.By Diagnosis
    • 4.3.1.Blood Test
    • 4.3.2.Allergy Test
    • 4.3.3.Physical Examination
    • 4.3.4.Others
  • 4.4.By Route of Administration
    • 4.4.1.Oral
    • 4.4.2.Topical
    • 4.4.3.Parenteral
    • 4.4.4.Others
  • 4.5.By End-user
    • 4.5.1.Hospitals
    • 4.5.2.Specialty Clinics
    • 4.5.3.Homecare
    • 4.5.4.Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Chronic Spontaneous Urticaria Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Treatment
      • 5.1.2.1.Medication
      • 5.1.2.2.Plasmapheresis
      • 5.1.2.3.Phototherapy
      • 5.1.2.4.Others
    • 5.1.3.By Diagnosis
      • 5.1.3.1.Blood Test
      • 5.1.3.2.Allergy Test
      • 5.1.3.3.Physical Examination
      • 5.1.3.4.Others
    • 5.1.4.By Route of Administration
      • 5.1.4.1.Oral
      • 5.1.4.2.Topical
      • 5.1.4.3.Parenteral
      • 5.1.4.4.Others
    • 5.1.5.By End-user
      • 5.1.5.1.Hospitals
      • 5.1.5.2.Specialty Clinics
      • 5.1.5.3.Homecare
      • 5.1.5.4.Others
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Treatment
      • 5.1.6.2.1.Medication
      • 5.1.6.2.2.Plasmapheresis
      • 5.1.6.2.3.Phototherapy
      • 5.1.6.2.4.Others
      • 5.1.6.3.By Diagnosis
      • 5.1.6.3.1.Blood Test
      • 5.1.6.3.2.Allergy Test
      • 5.1.6.3.3.Physical Examination
      • 5.1.6.3.4.Others
      • 5.1.6.4.By Route of Administration
      • 5.1.6.4.1.Oral
      • 5.1.6.4.2.Topical
      • 5.1.6.4.3.Parenteral
      • 5.1.6.4.4.Others
      • 5.1.6.5.By End-user
      • 5.1.6.5.1.Hospitals
      • 5.1.6.5.2.Specialty Clinics
      • 5.1.6.5.3.Homecare
      • 5.1.6.5.4.Others
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Treatment
  • 6.2.By Diagnosis
  • 6.3.By Route of Administration
  • 6.4.By End-user
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.F. Hoffmann-La Roche Ltd.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Teva Pharmaceutical Industries Ltd.
  • 13.3.Sanofi S.A.
  • 13.4.Pfizer Inc.
  • 13.5.GlaxoSmithKline plc
  • 13.6.Novartis AG
  • 13.7.Bayer AG
  • 13.8.Eli Lilly and Company
  • 13.9.Merck & Co., Inc.
  • 13.10.AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3.Global Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 4.Global Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 5.Global Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6.Global Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 7.Global Chronic Spontaneous Urticaria Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10.North America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 11.North America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 12.North America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13.North America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 14.North America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17.United States Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 18.United States Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 19.United States Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20.United States Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 21.Canada Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23.Canada Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 24.Canada Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 25.Canada Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26.Canada Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 27.Mexico Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29.Mexico Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 30.Mexico Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 31.Mexico Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32.Mexico Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35.Europe Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 36.Europe Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 37.Europe Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38.Europe Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 39.Europe Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42.Germany Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 43.Germany Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 44.Germany Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45.Germany Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 46.France Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48.France Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 49.France Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 50.France Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51.France Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 52.Italy Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54.Italy Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 55.Italy Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 56.Italy Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57.Italy Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 58.United Kingdom Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 61.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 62.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 64.Russia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66.Russia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 67.Russia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 68.Russia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69.Russia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 70.Netherlands Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 73.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 74.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75.Netherlands Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 76.Spain Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78.Spain Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 79.Spain Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 80.Spain Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81.Spain Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 82.Turkey Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84.Turkey Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 85.Turkey Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 86.Turkey Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87.Turkey Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 88.Poland Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90.Poland Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 91.Poland Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 92.Poland Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93.Poland Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 94.South America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96.South America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 97.South America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 98.South America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.South America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 100.South America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103.Brazil Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 104.Brazil Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 105.Brazil Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106.Brazil Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 107.Argentina Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109.Argentina Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 110.Argentina Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 111.Argentina Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112.Argentina Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 113.Asia-Pacific Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 116.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 117.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 119.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 120.India Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122.India Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 123.India Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 124.India Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125.India Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 126.China Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128.China Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 129.China Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 130.China Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131.China Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 132.Japan Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134.Japan Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 135.Japan Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 136.Japan Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137.Japan Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 138.Australia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140.Australia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 141.Australia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 142.Australia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143.Australia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 144.Vietnam Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 147.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 148.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149.Vietnam Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 150.South Korea Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152.South Korea Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 153.South Korea Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 154.South Korea Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155.South Korea Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 156.Indonesia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 159.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 160.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161.Indonesia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 162.Philippines Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164.Philippines Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 165.Philippines Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 166.Philippines Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167.Philippines Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 168.Middle East & Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 171.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 172.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 174.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 178.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 179.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 181.UAE Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183.UAE Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 184.UAE Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 185.UAE Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186.UAE Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 187.South Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189.South Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 190.South Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 191.South Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192.South Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 193.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023